JP2024503698A5 - - Google Patents
Info
- Publication number
- JP2024503698A5 JP2024503698A5 JP2023543034A JP2023543034A JP2024503698A5 JP 2024503698 A5 JP2024503698 A5 JP 2024503698A5 JP 2023543034 A JP2023543034 A JP 2023543034A JP 2023543034 A JP2023543034 A JP 2023543034A JP 2024503698 A5 JP2024503698 A5 JP 2024503698A5
- Authority
- JP
- Japan
- Prior art keywords
- rbm
- fusion protein
- vaccine according
- cov
- sars
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163138228P | 2021-01-15 | 2021-01-15 | |
| US63/138,228 | 2021-01-15 | ||
| US202163140921P | 2021-01-24 | 2021-01-24 | |
| US63/140,921 | 2021-01-24 | ||
| US202163161439P | 2021-03-15 | 2021-03-15 | |
| US63/161,439 | 2021-03-15 | ||
| US202163173972P | 2021-04-12 | 2021-04-12 | |
| US63/173,972 | 2021-04-12 | ||
| US202163193558P | 2021-05-26 | 2021-05-26 | |
| US63/193,558 | 2021-05-26 | ||
| US202163222930P | 2021-07-16 | 2021-07-16 | |
| US63/222,930 | 2021-07-16 | ||
| US202163241944P | 2021-09-08 | 2021-09-08 | |
| US63/241,944 | 2021-09-08 | ||
| US202163283795P | 2021-11-29 | 2021-11-29 | |
| US63/283,795 | 2021-11-29 | ||
| US202163284565P | 2021-11-30 | 2021-11-30 | |
| US63/284,565 | 2021-11-30 | ||
| PCT/US2022/012607 WO2022155524A1 (en) | 2021-01-15 | 2022-01-14 | Variant strain-based coronavirus vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024503698A JP2024503698A (ja) | 2024-01-26 |
| JP2024503698A5 true JP2024503698A5 (enExample) | 2025-04-14 |
Family
ID=80222159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023543034A Pending JP2024503698A (ja) | 2021-01-15 | 2022-01-14 | 変異型株ベースのコロナウイルスワクチン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240100151A1 (enExample) |
| EP (1) | EP4277655A1 (enExample) |
| JP (1) | JP2024503698A (enExample) |
| AU (1) | AU2022208057A1 (enExample) |
| CA (1) | CA3208486A1 (enExample) |
| WO (1) | WO2022155524A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
| CN108430456B (zh) | 2015-10-22 | 2022-01-18 | 摩登纳特斯有限公司 | 癌症疫苗 |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| JP6983455B2 (ja) | 2016-09-14 | 2021-12-17 | モデルナティーエックス， インコーポレイテッド | 高純度ｒｎａ組成物及びその調製のための方法 |
| CN110167587A (zh) | 2016-11-11 | 2019-08-23 | 摩登纳特斯有限公司 | 流感疫苗 |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| CN111212905A (zh) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | Rna聚合酶变体 |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| JP2022521094A (ja) | 2019-02-20 | 2022-04-05 | モデルナティエックス インコーポレイテッド | 共転写キャッピング用ｒｎａポリメラーゼバリアント |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| JP2023525936A (ja) * | 2020-05-18 | 2023-06-19 | 康希諾（上海）生物科技有限公司 | ｍＲＮＡ又はｍＲＮＡ組成物、その調製方法及び使用 |
| US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| WO2022150717A1 (en) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Seasonal rna influenza virus vaccines |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US20240382581A1 (en) * | 2021-07-09 | 2024-11-21 | Modernatx, Inc. | Pan-human coronavirus vaccines |
| US12397051B2 (en) * | 2021-09-14 | 2025-08-26 | Globe Biotech Limited | Vaccine for use against coronavirus and variants thereof |
| WO2023092069A1 (en) * | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines and methods of use |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| EP4577236A1 (en) * | 2022-08-22 | 2025-07-02 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Vaccines against coronaviruses |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| WO2025166202A1 (en) | 2024-01-31 | 2025-08-07 | Modernatx, Inc. | Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1903054A3 (de) | 2001-06-05 | 2008-07-23 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie |
| JP4691495B2 (ja) * | 2004-07-15 | 2011-06-01 | 一般財団法人化学及血清療法研究所 | コロナウイルススパイクｓ１融合蛋白及びその発現ベクター |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| WO2009003222A1 (en) | 2007-06-29 | 2009-01-08 | Commonwealth Scientific And Industrial Research Organisation | Methods for degrading toxic compounds |
| EP3156414B1 (en) | 2007-09-26 | 2019-12-04 | Intrexon Corporation | Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression |
| CN103911378A (zh) | 2007-12-11 | 2014-07-09 | 斯克利普斯研究所 | 涉及mRNA翻译增强因子的组合物和方法 |
| PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| WO2013185069A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| EP2971033B8 (en) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
| EP4614148A3 (en) | 2013-03-15 | 2025-12-17 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| AU2014310933B2 (en) | 2013-08-21 | 2020-05-14 | CureVac SE | Method for increasing expression of RNA-encoded proteins |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| WO2015101415A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
| CN111304231A (zh) | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| DK3134131T3 (en) * | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| AU2016342048B2 (en) * | 2015-10-22 | 2022-09-08 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| MD3718565T2 (ro) * | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| JP6983455B2 (ja) | 2016-09-14 | 2021-12-17 | モデルナティーエックス， インコーポレイテッド | 高純度ｒｎａ組成物及びその調製のための方法 |
| CN111212905A (zh) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | Rna聚合酶变体 |
| JP2023511633A (ja) * | 2020-01-28 | 2023-03-20 | モデルナティエックス インコーポレイテッド | コロナウイルスｒｎａワクチン |
| EP3886897A1 (en) * | 2020-02-04 | 2021-10-06 | CureVac AG | Coronavirus vaccine |
| AU2021215938A1 (en) * | 2020-02-07 | 2022-09-01 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines |
| WO2021213945A1 (en) * | 2020-04-22 | 2021-10-28 | Pfizer Inc. | Coronavirus vaccine |
| WO2021226436A1 (en) * | 2020-05-07 | 2021-11-11 | Translate Bio, Inc. | Optimized nucleotide sequences encoding sars-cov-2 antigens |
-
2022
- 2022-01-14 JP JP2023543034A patent/JP2024503698A/ja active Pending
- 2022-01-14 CA CA3208486A patent/CA3208486A1/en active Pending
- 2022-01-14 AU AU2022208057A patent/AU2022208057A1/en not_active Abandoned
- 2022-01-14 WO PCT/US2022/012607 patent/WO2022155524A1/en not_active Ceased
- 2022-01-14 EP EP22703172.1A patent/EP4277655A1/en active Pending
- 2022-01-14 US US18/272,512 patent/US20240100151A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024503699A5 (enExample) | ||
| JP2023513073A5 (enExample) | ||
| JP2024513999A5 (enExample) | ||
| JP2024514182A5 (enExample) | ||
| ES3058501T3 (en) | Rsv f protein mutants | |
| ES2869199T3 (es) | Sistemas de expresión | |
| JP2022136230A5 (enExample) | ||
| TW202140518A (zh) | 冠狀病毒疫苗 | |
| IL278418B2 (en) | Vaccine composition | |
| JP2024542188A5 (enExample) | ||
| JP2024156964A5 (enExample) | ||
| TW201202262A (en) | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | |
| JP2023546369A5 (enExample) | ||
| Ibañez et al. | M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A | |
| JP2022533318A (ja) | 気道感染の治療または予防のためのサブユニットワクチン | |
| BR112012024872B1 (pt) | Composições farmacêuticas compreendendo um polipeptídeo contendo pelo menos um motivo cxxc e antígenos heterólogos e seus usos | |
| JP2017538672A (ja) | Ｃｍｖ由来改変ウイルス様粒子 | |
| JP2013523887A5 (enExample) | ||
| JP2024542635A5 (enExample) | ||
| JP2010536878A (ja) | インフルエンザタンパク質を製造および使用する組成物および方法 | |
| JP2019088329A5 (enExample) | ||
| JP2024539512A5 (enExample) | ||
| JP2021511077A (ja) | インフルエンザウイルスワクチン及びその使用 | |
| JP2020519663A (ja) | Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物 | |
| JP2023532290A5 (enExample) |